Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
| Autor: | Yang, Yunpeng *, Qu, Song *, Li, Jingao *, Hu, Chaosu *, Xu, Mingjun *, Li, Weidong *, Zhou, Ting *, Shen, Liangfang, Wu, Hui, Lang, Jinyi, Hu, Guangyuan, Luo, Zhanxiong, Fu, Zhichao, Qu, Shenhong, Feng, Weineng, Chen, Xiaozhong, Lin, Shaojun, Zhang, Weimin, Li, Xiaojiang, Sun, Yan, Lin, Zhixiong, Lin, Qin, Lei, Feng, Long, Jianting, Hong, Jinsheng, Huang, Xiaoming, Zeng, Lingzhi, Wang, Peiguo, He, Xiaohui, Zhang, Ben, Yang, Qing, Zhang, Xiaojing, Zou, Jianjun, Fang, Wenfeng, Zhang, Li * |
|---|---|
| Zdroj: | In The Lancet Oncology August 2021 22(8):1162-1174 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|